Table 1.

In vivo and in vitro study design.

In Vivo Studies Stratified by Arsenic Exposure Duration
Duration	Arsenic Dose	Type	Method	Model	Citation
2 h	0.15 μM, 1.5 μM, 5 μM	As2O3	IV 1	Wistar rat	[59]
	1.5 μM	As2O3	IV	Guinea pig	[58]
6–10 days	0.8 mg/kg	As2O3	IV	Wistar rat	[64]
	1 mg/kg	As2O3	IV	Balb/c mouse	[72]
	3 mg/kg	As2O3	IV	Wistar rat	[33]
	10 mg/kg	NaAsO2	Oral	Wistar rat	[68]
	10 mg/kg	NaAsO2	Oral	Wistar rat	[67]
10–29 days	1 mg/kg	As2O3	IV	Balb/c mouse	[62]
	2.5 mg/kg	As2O3	IP 2	Wistar rat	[63]
	5 mg/kg	As2O3	IP	Wistar rat	[54]
	5 mg/kg	As2O3	Oral	SD rat 3	[70]
	5 mg/kg	NaAsO2	Oral	Wistar rat	[56]
	200 ppb	NaAsO2	Oral	APO E-/-	[71]
30–56 days	2 mg/kg	NaAsO2	Oral	SD rat	[69]
	4 mg/kg	As2O3	Oral intubation	Wistar rat	[57]
	4 mg/kg	As2O3	Oral intubation	Wistar rat	[57]
	4 mg/kg	As2O3	Oral	Wistar rat	[32]
	5 mg/kg	As2O3	IV	SD rat	[59]
	10 mg/kg	NaAsO2	Oral	SD rat	[55]
	50 mg/kg	NaAsO2	Oral	SD rat	[49]
In Vitro Studies
	1 μM	NaAsO2		H9c2 4	[49]
	1 μM, 2 μM	As2O3		H9c2	[60]
	2 μM/mL	As2O3		H9c2	[61]
	4 μM	As2O3		H9c2	[62]
	5 μM	As2O3		NRLVM 5	[65]
	5 μM	As2O3		H9c2	[66]
	5 μM	As2O3		H9c2	[45]
	5 μM	NaAsO2		Primary myocytes	[69]
	5 μM, 7.5 μM, 10 μM	As2O3		H9c2	[73]
	5 μM, 6 μM, 12 μM	As2O3		NRLVM	[64]
	10 μM	As2O3		H9c2	[57]
	10 μM	NaAsO2		H9c2	[72]

¹ Intravenous; ² intraperitoneal; ³ Sprague Dawley; ⁴ H9c2-rat heart cardiomyocyte cells; ⁵ neonatal rat left ventricular myocytes.